Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
xentuzumab
- Development stage
- Phase 2
- Lead developer
- Boehringer Ingelheim
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Xentuzumab is a humanized IgG1 monoclonal antibody that targets and neutralizes insulin-like growth factor 1 (IGF-1) and insulin-like growth factor 2 (IGF-2) ligands. By binding to these ligands, xentuzumab inhibits their proliferative activity and blocks IGF-mediated signaling pathways involved in tumor cell growth and survival. This mechanism restores inhibition of the AKT pathway when used in combination with other agents such as everolimus. Xentuzumab has been investigated primarily for the treatment of advanced solid tumors, including hormone receptor-positive/HER2-negative breast cancer, non-small cell lung cancer (NSCLC), and metastatic castration-resistant prostate cancer[2][3][4][5][9][10].
- Brand names
- xentuzumab
02
Targets
IGF-1 (Insulin-like growth factor 1)IGF2 (Insulin-like growth factor 2)
Beyond the preview
Go deeper on xentuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on xentuzumab.